The early promise offered by cell therapies and gene therapies is tempered by the challenges associated with developing, manufacturing, and delivering the drug product to patients. This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Contract development and manufacturing organizations need to play a critical role in the scale-up and industrialization of cellular therapies by providing customized tools and processes. The "manufacturing by design" approach for addressing the industrialization of cell therapies allows for optimal production conditions.
Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. This webinar presents a clinical-to-commercial perspective on autologous therapies.